MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, DRMA has $5,071,410 in assets. $1,111,308 in debts. $4,664,127 in cash and cash equivalents.

Balance Sheets Overview

Debt to Asset Ratio
21.91%
Assets Breakdown
    • Cash and cash equivalents
    • Prepaid expenses and other curre...
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued and other current liabil...
    • Others

Unit: Dollar
Balance Sheets
2025-09-30
2025-06-30
Cash and cash equivalents
4,664,127 6,480,930
Prepaid expenses and other current assets
407,283 159,586
Total assets
5,071,410 6,640,516
Accounts payable (including related party amounts of 185,300 and 0, respectively)
453,427 413,687
Accrued and other current liabilities (including related party amounts of 28,600 and 0, respectively)
657,881 612,578
Total liabilities
1,111,308 1,026,265
Common stock, par value 0.0001 per share, 250,000,000 shares authorized 844,457 shares issued and outstanding as of september 30, 2025 251,725 shares issued and outstanding as of december 31, 2024
84 64
Additional paid-in capital
75,332,026 75,294,206
Accumulated deficit
-71,372,008 -69,680,019
Total stockholders equity
3,960,102 5,614,251
Total liabilities and stockholders equity
5,071,410 6,640,516
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Prepaid expenses andother current assets$407,283 Cash and cashequivalents$4,664,127 Total assets$5,071,410 Total liabilities andstockholders equity$5,071,410 Total stockholdersequity$3,960,102 Total liabilities$1,111,308 Accumulated deficit-$71,372,008 Additional paid-in capital$75,332,026 Accrued and othercurrent liabilities...$657,881 Accounts payable(including related party...$453,427 Common stock, par value0.0001 per share,...$84

Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc. (DRMA)